Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 9/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544780 | 1.00 | CNR2 (0.34) | CNR2PDE2AUTS2RCNR1MRGPRX4 | |
| SCHEMBL1742907 | 0.92 | PDE2A (0.33) | CNR2PDE2AUTS2REEF2K | |
| SCHEMBL2547956 | 0.92 | PDE2A (0.33) | CNR2PDE2AUTS2REEF2K | |
| SCHEMBL12241696 | 0.89 | PPARG (0.38) | PDE2AUTS2RPPARGPPARA | |
| SCHEMBL1595431 | 0.86 | PDE2A (0.39) | CNR2PDE2AEEF2K | |
| SCHEMBL1595429 | 0.86 | PDE2A (0.39) | CNR2PDE2AEEF2K | |
| SCHEMBL12241674 | 0.82 | PPARG (0.41) | CNR2EEF2KPPARGPPARAFFAR1 | |
| SCHEMBL1742724 | 0.82 | PPARG (0.41) | CNR2EEF2KPPARGPPARAFFAR1 | |
| SCHEMBL1742024 | 0.82 | PPARG (0.41) | CNR2EEF2KPPARGPPARAFFAR1 | |
| SCHEMBL2548040 | 0.81 | GPR139 (0.35) | PDE2AUTS2RFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | CNR2 2228/4885PDE2A 2083/4885UTS2R 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.